SLC6A9 and thyroid cancer: Because the present study showed that SLC6A9 significantly maintained 131I sensitivity of thyroid cancer in vitro, our study did not investigate the systematic effects of SCL6A9 considering the target efficiency in PTC tumors that is an important point in the decision making process of molecular target treatment.